The Enantiomer of ADB-FUBINACA is defined in a 2009 Pfizer patent and has been stated to be a strong agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3. five nM, respectively. ADB-FUBINACA capabilities a carboxamide organization on the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA seems to be made from rational drug design because it differs from AB-FUBINACA handiest via way of means of substituting the isopropyl organization with a tert-butyl organization. An analog of ADB-FUBINACA, ADSB-FUB-187, containing an extra functionalized carboxamide substituent changed into lately stated.
Saara Sallinen
The Real Estate Professor, Platinum Realty
98win
Osman Mohamed
Benjamin Cruz
Hm88 Gb Net
789p Moe
Earthen Stoneworks
Phil Acker
Xbet India